1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
BICO Group AB (publ)

BICO Group AB (publ)

BICO.ST
BICO Group AB (publ)SE flagStockholm Stock Exchange
14.90
SEK
-1.56
- -
1.03BMarket Cap
BICO Group AB (publ)
BICO.ST
(Stockholm Stock Exchange)

Recent

price

14.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.49
1.47
3.02
4.19
21.96
32.96
28.49
24.47
21.21
21.86
Revenue per Share
- -
-0.03
0.04
0.02
-1.47
-3.97
-12.94
-16.62
-0.08
-15.43
-4.5
Basic EPS, GAAP
- -
-0.55
-1.02
-1.48
-3.65
-11.81
-12.42
-1.6
1.03
0.61
3.05
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.04
-0.01
0.06
0.08
-1.4
-4.75
-17.17
-68.74
-68.86
-84.31
-74.79
Book Value per Share
0.14
1.68
5.05
4.58
25.92
4.89
3.41
-1.25
0.15
6.43
0.16
Tangible Book Value per Share
7
27
31
35
42
57
64
71
71
71
71
Basic Weighted Avg Shares
- -
13
45
105
177
1,257
2,121
2,010
1,727
1,497
1,543
Sales/Revenue/Turnover
- -
-4.33
-1.58
-5.89
-37.38
-21.53
-15.22
-14.59
-11.5
-16.42
-16.58
Operating Margin (%)
- -
- -
3
7
26
192
941
1,144
478
1,272
258
Depreciation Expense
- -
-1
1
1
-62
-228
-833
-1,173
-6
-1,089
-318
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-5.37
2.61
0.55
-35.01
-18.1
-39.27
-58.33
-0.32
-72.73
-20.58
Profit Margin (%)
4
47
154
162
1,061
1,924
1,498
1,194
1,284
430
-13
Working Capital
3
3
1
1
48
1,548
1,755
1,856
1,670
218
248
LT Debt
3
60
186
550
1,523
6,803
6,932
3,100
3,008
1,749
2,464
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
24.74
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
94
1,150
1,158
LT Borrowings
1,337
2
- -
LT Finance Leases
332
256
248
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
71
71
71
Market Capitalization
2,260
2,155
2,532

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,854
1,725
1,642
Cash, Cash Equivalents & STI
598
596
548
Accounts Receivable, Net
451
229
233
Inventories
259
247
234
Total Current Liabilities
571
1,626
1,654
Payables & Accruals
- -
- -
- -
ST Debt
94
1,150
1,158
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
49.71%
-41.86%
Free Cash Flow
- -
13.25%
-40.3%
Net Income, GAAP
- -
4,034.63%
19,698.18%
Sales/Revenue/Turnover
- -
129.45%
-13.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
470
423
369
515
1,727
2025
335
324
451
- -
1,497
2026
330
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.4
-1.1
-3.49
4.91
-0.08
2025
-3.31
-2.61
-0.84
- -
-15.43
2026
-1.86
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
TriSalus Life Sciences, Inc. (TLSI)
AVRA Medical Robotics, Inc. (AVMR)
Telesis Bio, Inc. (TBIO)
Tandem Diabetes Care, Inc. (TNDM)
Shanghai Sanyou Medical Co., Ltd. (688085.SS)
Isoray, Inc. (ISR)
Business
BICO Group AB (publ) (STO: BICO) develops, manufactures and commercializes lab automation software, hardware and integrated solutions for life science research, diagnostics manufacturing and biopharmaceutical applications; its core offerings span three primary segments including Bioprinting with 3D bioprinters, bioinks and related services from brands such as CELLINK for tissue engineering, 3D in vitro models and drug discovery; Life Science Solutions encompassing advanced instrumentation and consumables for cell culture, imaging, sorting, sample preparation, single-cell and spheroid dispensing, liquid handling such as the I.DOT series from SCIENION and DISPENDIX, hybrid microscopes from NANO-CELLECT, mixing solutions from Flownova, and extracellular matrix proteins from Advanced BioMatrix; and Lab Automation featuring the proprietary hardware-agnostic Green Button Go Suite software alongside automation integration, engineering and consulting services from Biosero to enable connected workflows and end-to-end laboratory systems. Incorporated in 2016 and headquartered in Gothenburg, Sweden, the company operates globally across North America, Europe and Asia with sales organizations and distributor networks serving pharmaceutical, biopharmaceutical, biotechnology, diagnostics, academia, research and cosmetics sectors; it maintains over 48,000 instruments in the field across more than 25 countries and boasts citations in over 12,000 publications. Formerly known as Cellink AB (publ), BICO rebranded in August 2021; recent developments include the divestiture of MatTek Corp. and Visikol Inc. to Sartorius for net proceeds of USD 77.2 million completed in July 2025 following regulatory approval to streamline focus on lab automation and high-margin workflows, repurchase of convertible bonds totaling SEK 276 million nominal in February 2025 and an additional SEK 98 million in August 2025 to optimize capital structure, launch of the I.DOT LT non-contact liquid handler by DISPENDIX in May 2025 for precise nano-to-microliter dispensing in NGS, PCR and assays, a Biosero contract for integrated lab automation solutions valued at USD 15.2 million announced in September 2025, strategic leadership and process enhancements at Biosero including new management and gate-stage project models to address capacity constraints amid high demand, and an updated BICO 2.0 strategy unveiled at the Capital Markets Day in September 2024 emphasizing commercial excellence, operational synergies and sustainable growth through end-to-end automation, AI integration and recurring revenue expansion.